I have always thought the NEU strategy was (can’t remember what lead me to this) that Trofenitide would be sold as a stand alone drug, and that enough work would be done on NNZ-2591 to realize optimum value, with an ultimate sale of the drug in total.
Ill admit that things seem to have moved from there - to NEU possibly going the whole way alone / but the bottom line is that if a sale was to materialise for NEU I never thought that Trofenitide would be part of it.
So the RoW rights doesn’t impact this approach.
Acadia, page-56
-
- There are more pages in this discussion • 622 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |